Last reviewed · How we verify

Depigoid Parietaria judaica 1000DPP/ml

Laboratorios Leti, S.L. · Phase 3 active Biologic

Depigoid Parietaria judaica 1000DPP/ml is a Allergen immunotherapy extract Biologic drug developed by Laboratorios Leti, S.L.. It is currently in Phase 3 development for Allergic rhinitis caused by Parietaria judaica pollen sensitization, Allergic asthma associated with Parietaria judaica pollen allergy. Also known as: A suspension of depigmented and glutaraldehyde-polymerised allergen extract of Parietaria judaica adsorbed onto aluminium hydroxide..

Depigoid is an allergen extract-based immunotherapeutic that desensitizes the immune system to Parietaria judaica pollen through gradual exposure, reducing allergic responses.

Depigoid is an allergen extract-based immunotherapeutic that desensitizes the immune system to Parietaria judaica pollen through gradual exposure, reducing allergic responses. Used for Allergic rhinitis caused by Parietaria judaica pollen sensitization, Allergic asthma associated with Parietaria judaica pollen allergy.

At a glance

Generic nameDepigoid Parietaria judaica 1000DPP/ml
Also known asA suspension of depigmented and glutaraldehyde-polymerised allergen extract of Parietaria judaica adsorbed onto aluminium hydroxide.
SponsorLaboratorios Leti, S.L.
Drug classAllergen immunotherapy extract
ModalityBiologic
Therapeutic areaImmunology / Allergy
PhasePhase 3

Mechanism of action

Depigoid contains standardized allergen extracts from Parietaria judaica (wall pellitory) pollen and works through allergen immunotherapy (AIT) principles. By administering increasing doses of the allergen, it promotes immune tolerance through shift toward regulatory T cells and IgG-blocking antibodies, thereby reducing IgE-mediated allergic reactions. This approach is designed to provide long-term clinical benefit and reduce symptoms in allergic rhinitis and potentially allergic asthma.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Depigoid Parietaria judaica 1000DPP/ml

What is Depigoid Parietaria judaica 1000DPP/ml?

Depigoid Parietaria judaica 1000DPP/ml is a Allergen immunotherapy extract drug developed by Laboratorios Leti, S.L., indicated for Allergic rhinitis caused by Parietaria judaica pollen sensitization, Allergic asthma associated with Parietaria judaica pollen allergy.

How does Depigoid Parietaria judaica 1000DPP/ml work?

Depigoid is an allergen extract-based immunotherapeutic that desensitizes the immune system to Parietaria judaica pollen through gradual exposure, reducing allergic responses.

What is Depigoid Parietaria judaica 1000DPP/ml used for?

Depigoid Parietaria judaica 1000DPP/ml is indicated for Allergic rhinitis caused by Parietaria judaica pollen sensitization, Allergic asthma associated with Parietaria judaica pollen allergy.

Who makes Depigoid Parietaria judaica 1000DPP/ml?

Depigoid Parietaria judaica 1000DPP/ml is developed by Laboratorios Leti, S.L. (see full Laboratorios Leti, S.L. pipeline at /company/laboratorios-leti-s-l).

Is Depigoid Parietaria judaica 1000DPP/ml also known as anything else?

Depigoid Parietaria judaica 1000DPP/ml is also known as A suspension of depigmented and glutaraldehyde-polymerised allergen extract of Parietaria judaica adsorbed onto aluminium hydroxide..

What drug class is Depigoid Parietaria judaica 1000DPP/ml in?

Depigoid Parietaria judaica 1000DPP/ml belongs to the Allergen immunotherapy extract class. See all Allergen immunotherapy extract drugs at /class/allergen-immunotherapy-extract.

What development phase is Depigoid Parietaria judaica 1000DPP/ml in?

Depigoid Parietaria judaica 1000DPP/ml is in Phase 3.

What are the side effects of Depigoid Parietaria judaica 1000DPP/ml?

Common side effects of Depigoid Parietaria judaica 1000DPP/ml include Local injection site reactions (itching, swelling, erythema), Oral allergy syndrome or local oral symptoms, Systemic allergic reactions, Rhinitis or asthma exacerbation.

Related